Literature DB >> 31319433

Linear IgA bullous dermatosis associated with ulcerative colitis: A case report and literature review.

Naoko Kanda1, Nanami Nakadaira1, Yohei Otsuka1, Norito Ishii2, Toshihiko Hoashi3, Hidehisa Saeki3.   

Abstract

We report the case of a 59-year-old Japanese woman who developed linear IgA bullous dermatosis during treatment for ulcerative colitis that manifested as pruritic vesicles with erythema on the trunk and scalp. Histopathological examination revealed subepidermal bulla with neutrophil and eosinophil infiltration in the upper dermis. Direct immunofluorescence revealed linear IgA deposits at the basement membrane zone, and indirect immunofluorescence using split skin revealed IgA reaction to the epidermal side (lamina lucida type). We reviewed 33 reported cases of linear IgA bullous dermatosis associated with ulcerative colitis and found that ulcerative colitis preceded the onset of linear IgA bullous dermatosis in 94% of the patients and that IgA-positive patients in split skin indirect immunofluorescence all showed the lamina lucida type, indicating that target antigens for serum IgA antibodies may reside in the lamina lucida. Regarding the pathogenetic association of ulcerative colitis and linear IgA bullous dermatosis, intestinal inflammation may induce the exposure and presentation of intestinal antigens that are cross-reactive to cutaneous antigens, stimulating autoimmune response to antigens of cutaneous basement membrane zones.
© 2019 The Australasian College of Dermatologists.

Entities:  

Keywords:  antigen; basement membrane zone; lamina lucida; linear IgA bullous dermatosis; ulcerative colitis

Mesh:

Year:  2019        PMID: 31319433     DOI: 10.1111/ajd.13121

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  1 in total

1.  Eosinophil-rich linear IgA bullous dermatosis induced by mRNA COVID-19 booster vaccine.

Authors:  William J Nahm; Michelle Juarez; Julie Wu; Randie H Kim
Journal:  J Cutan Pathol       Date:  2022-08-03       Impact factor: 1.458

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.